SANTA CLARA, Calif.--(BUSINESS WIRE)--Mar. 19, 2014--
Agilent Technologies Inc. (NYSE: A) today announced that George A.
Scangos, Ph.D., chief executive officer and director of Biogen Idec
Inc., has been appointed to Agilent’s board of directors and will join
the board in September.
“I am delighted to welcome Dr. Scangos to the board,” said James G.
Cullen, Agilent chairman. “He has an extraordinary combination of
biotechnology and business expertise along with insights that come from
running a large successful global pharma company.”
Prior to Biogen, Scangos served as president and CEO of Exelixis Inc., a
drug discovery and development company. He was previously president of
Bayer Biotechnology.
“I am very pleased to join the Agilent board and work with this
excellent team,” Scangos said. “The company has a strong history of
innovation and integrity, and I look forward to contributing to its
future direction and growth as a global leader in life sciences,
diagnostics and applied markets.”
Scangos replaces Dr. David Lawrence, who is retiring from the Agilent
board after 13 years of service.
“I would like to thank Dave for his guidance and leadership on our board
since the inception of Agilent,” said Cullen.
Scangos is currently an adjunct professor of biology at Johns Hopkins
University. He was previously a professor of biology there for six
years. Scangos was non-executive chairman of Anadys Pharmaceuticals
Inc., a biopharmaceutical company, from 2005 to 2010. He has been chair
of the California Healthcare Institute and a member of the board of the
Global Alliance for TB Drug Development. He is also a member of the
National Board of Visitors of the University of California Davis School
of Medicine.
“Dr. Scangos brings significant knowledge and experience from the
biotech, healthcare and pharmaceutical industries, as well as
comprehensive leadership resulting from his work as a director on
various boards,” said William (Bill) Sullivan, Agilent president and
CEO. “Dr. Scangos will be a great addition to our board as we re-launch
Agilent with a focus on life sciences, diagnostics and applied markets.”
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement
company and a technology leader in chemical analysis, life sciences,
diagnostics, electronics and communications. The company’s 20,600
employees serve customers in more than 100 countries. Agilent had
revenues of $6.8 billion in fiscal 2013. Information about Agilent is
available at www.agilent.com.
On Sept. 19, 2013, Agilent announced plans to separate into two publicly
traded companies through a tax-free spinoff of its electronic
measurement business. The new company is named Keysight Technologies,
Inc. The separation is expected to be completed in early November 2014.
NOTE TO EDITORS: Further technology, corporate citizenship and executive
news is available at www.agilent.com/go/news.
Source: Agilent Technologies Inc.
Agilent Technologies Inc.
EDITORIAL CONTACT:
Michele Drake, +1
408-345-8396
michele_drake@agilent.com
or
INVESTOR
CONTACT:
Alicia Rodriguez, +1 408-345-8948
alicia_rodriguez@agilent.com